Novartis' Newly FDA-Approved Rare Blood Disorder Drug Aces Phase 3 Study In Ultra Rare Kidney Failure Disease
Portfolio Pulse from Vandana Singh
Novartis AG (NYSE:NVS) reported positive Phase 3 study results for iptacopan in treating C3 glomerulopathy (C3G), a rare kidney disease. The study met its primary endpoint, showing significant proteinuria reduction. Iptacopan, branded as Fabhalta, was recently FDA-approved for a rare blood disorder. Regulatory submissions for C3G treatment are expected in 2024. NVS shares rose 0.53% in premarket trading.
December 11, 2023 | 12:56 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Novartis AG's iptacopan shows promise in Phase 3 study for C3G, complementing its recent FDA approval for another rare disease. Shares are responding positively.
The positive study results for iptacopan in treating C3G, along with its recent FDA approval for a different condition, are likely to be viewed favorably by investors, potentially leading to a short-term increase in NVS stock price. The premarket share price movement supports this outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100